A Letter from Novartis 诺华公司的一封信

John Tsai

Global Drug Development

全球药品研发部

Dear Colleagues,

各位同事,

I hope by now you have had the opportunity to go through the quarterly results for Q3 2018, announced last week.

上周，我们公布了2018年第三季度业绩，各位现在应该都已了解了相关内容。

It is fair to say that they were impressive.

可以说，这样的业绩十分喜人。

I’m sure you feel as proud as I do of the contribution that the GDD organization has made to this success.

我相信大家和我一样，为GDD部门在其中所做的贡献而感到自豪。

For this quarter, we received key approvals and regulatory opinions for nine transformative treatments, including Aimovig for migraine prevention, Kymriah both for adults with DLBCL and children with ALL, Tafinlar/Mekinist for people with BRAF V600-mutant melanoma, Kisqali as a first-line treatment for HR+/HER2- metastatic breast cancer and Gilenya to treat children and adolescents with MS.

本季度，我们收到了九项变革性疗法的关键性批准和监管意见，其中包括用于预防偏头痛的药物Aimovig、用于治疗细胞淋巴瘤（DLBCL）成年患者和急性淋巴细胞白血病（ALL）儿童患者的药物Kymriah、用于治疗BRAF V600突变黑色素瘤患者的药物Tafinlar/Mekinist、用于一线治疗HR+/HER2转移性乳腺癌的药物Kisqali，以及用于治疗儿童及青少年多发性硬化症（MS）的药物Gilenya。

We achieved key regulatory submissions, including for siponimod in a difficult-to-treat stage of MS, and announced many more major trial results.

我们完成了主要的监管性提交，包括用于多发性硬化症难治性阶段的药物siponimod，而且公布了许多重要的试验结果。

We also announced our planned acquisition of Endocyte to accelerate development of novel radiopharmaceutical technology for treating cancer.

我们还宣布了收购Endocyte公司的计划，以加速开发用于治疗癌症的新型放射性药物技术。

All this and more, in Q3 alone.

所有这些都仅仅是第三季度所取得的成绩，当然，第三季度的成果还远不止这些。

And what is key is not just the quantity, but the quality of the milestones.

但这些成绩的关键并不在于数量，而在于其具有里程碑意义的质量。

In these successes – and even in our disappointments, such as the FDA’s decision not to support our application for canakinumab in CV risk reduction – we see tangible evidence of our bold approach to scientific innovation.

无论是我们获得的成功，还是遭遇的挫折，例如，FDA驳回了我们有关利用降低心血管疾病风险的申请，都有力地证明了我们在大胆进行科学创新。

To continue and build on this, we must drive medical innovation while simultaneously embracing external trends.

为了延续这一良好的发展势头，我们必须积极推动医疗创新，同时顺应行业发展趋势。

Since I joined GDD, I have consistently talked about the areas we must focus on to achieve this, with a clear emphasis on our portfolio, data and digital projects, operational excellence, and culture.

自加入GDD以来，我一直在谈论我们为实现这一目标而必须重点关注的领域，并明确要着重于产品组合、数据和数字化项目、卓越运营以及企业文化等方面。

In recent weeks, I have been working with members of the DCN to refine our GDD strategy to ensure it reflects our latest thinking, and I am pleased to share that with you now.

最近几周，我与DCN成员一道，改进完善了GDD战略，确保它能体现我们最新的想法和观点。我很高兴现在能与大家分享相关内容。

I want us all to be clear on our approach and the language we will use going forward when talking about our priorities.

我希望大家都清楚我们所遵循的方针，明白我们在未来讨论重点事项时将使用的表述。

I appreciate there is a lot of terminology used around our strategy and I want to simplify to ensure we are consistent in our understanding and our messaging across the organization.

之前的战略中使用了很多术语，这一点我很欣赏，但我想更简单一些，确保在整个部门中，理解和信息传递做到一致无误。

As you know, our purpose at Novartis is to Reimagine Medicine, which our company has done consistently for the last 100 years, contributing a huge amount to society during that time.

如你们所知，诺华的宗旨是重新定义医学，公司在过去百年里也一直在为此而努力，为社会做出了巨大的贡献。

We will only continue to be successful if we develop and implement a clear GDD strategy, as follows:

只有制定并实施明确的GDD战略，我们才能继续取得成功，其中包括：

·    Deliver breakthrough innovation:

     实现突破性创新：

We will continue to build a pipeline of innovative medicines that address high unmet needs and improve and extend people’s lives across the world.

我们将继续构建创新型药物的研发体系，解决全球范围内未满足的医疗需求，延长人们的寿命，改善生活质量。

We will achieve this by prioritizing the medicines that will have the most impact for patients, and by establishing the innovative platform technologies we need to deliver them.

我们将通过优先开发疗效最为显著的药物，并建立相应的创新型平台技术来实现这一目标。

·   Unleash the power of data and digital:

    释放数据和数字化的力量：

Data and digital will help us to identify these innovative medicines and accelerate their development.

数据和数字化技术将有助于发掘创新型药物，同时加速药物开发。

We will use all available data to generate insights about diseases, patients and treatments.

我们将充分利用各类可用数据，对疾病、患者和疗法进行深入研究。

We will use technologies that improve the patient experience, and we will embed tools to improve our end-to-end clinical trial processes.

我们将运用能改善患者体验的技术，同时借助各种工具改进端到端的临床试验流程。

·   Embrace operational excellence:

    迈向卓越运营：

Implementing a step-change in how we operate will bring these innovative and impactful medicines to patients as quickly as possible.

落实运营方式的重大变革，让有效的创新型药物尽早为患者带去福音。

We will implement better resource prioritization, simplified governance and strengthened NIBR / GDD collaboration to reduce our development cycle times.

我们将采用更加合理的资源优先次序，简化管理并加强NIBR与GDD的合作，缩短药物研发周期。

·   All underpinned by our inspired, curious and unbossed culture:

    以鼓舞人心、好奇求知、去领导化的文化为后盾：

We want everyone to feel inspired, empowered to be their best self, and to live our values and behaviors.

我们不断鼓舞每位员工，让他们奋发向上，充分发挥自身的价值，积极践行我们的价值观及行为方式。

We will support leaders to become more effective in role modelling and coaching, we will enable good decision-making, and we will further embed our culture throughout GDD.

我们会为领导者提供必要的支持，让他们起到更好的带头模范作用，让指导工作更加有效的开展；我们会让决策更加明智；我们还会在GDD整个部门内深入推广这种文化。

I hope you agree this is not a radical change in direction but rather an evolution.

我希望大家清楚，这并不是方向上的巨变，而是一种发展进步。

More detail can be found in these slides.

如需了解详细内容，可查看这些幻灯片。

I will also be providing further information on each element of this strategy over the coming weeks, starting with data and digital.

在接下来的几周里，我将从数据和数字化着手，详细介绍这一战略中的各个要素。

In the meantime, I want to thank you for the ongoing high quality of your work, which continues to impress me enormously.

同时，我要感谢大家一直以来对工作的倾情投入，你们的出色表现给我留下了深刻印象。

I believe that if we realize our strategy, we will go on to achieve even greater things, together.

我坚信，只要切实践行战略，我们就能共同再创佳绩。

Kind regards,

亲切问候,

John